- Home
- HNVR vs ACHV Comparison
HNVR vs ACHV Comparison
Compare HNVR & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HNVR | ACHV |
|---|---|---|
| Founded | 2008 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 167.7M | 167.6M |
| IPO Year | 2022 | N/A |
Fundamental Metrics
Financial Performance| Metric | HNVR | ACHV |
|---|---|---|
| Price | $24.10 | $4.50 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $24.75 | $15.50 |
| AVG Volume (30 Days) | 17.1K | ★ 599.1K |
| Earning Date | 01-28-2026 | 11-06-2025 |
| Dividend Yield | ★ 1.67% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.52 | N/A |
| Revenue | ★ $68,038,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $24.67 | N/A |
| P/E Ratio | $15.80 | ★ N/A |
| Revenue Growth | ★ 10.44 | N/A |
| 52 Week Low | $17.47 | $1.84 |
| 52 Week High | $27.00 | $5.78 |
Technical Indicators
Market Signals| Indicator | HNVR | ACHV |
|---|---|---|
| Relative Strength Index (RSI) | 73.94 | 49.12 |
| Support Level | $23.04 | $4.57 |
| Resistance Level | $23.38 | $4.86 |
| Average True Range (ATR) | 0.34 | 0.31 |
| MACD | 0.14 | -0.02 |
| Stochastic Oscillator | 96.21 | 37.81 |
Price Performance
Historical ComparisonAbout HNVR Hanover Bancorp Inc.
Hanover Bancorp Inc is a United States-based banking company. It offers a full range of financial services and employs a complete suite of consumer and commercial banking products and services, including multi-family and commercial mortgages, residential loans, business loans, and lines of credit.
About ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.